A Nurse-Led Palliative and Supportive Care Intervention for Newly Diagnosed Adults with Acute Myeloid Leukemia
针对新诊断的急性髓系白血病成人的护士主导的姑息和支持护理干预措施
基本信息
- 批准号:10368993
- 负责人:
- 金额:$ 19.44万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-03-09 至 2023-02-28
- 项目状态:已结题
- 来源:
- 关键词:Acute Myelocytic LeukemiaAddressAdultAdverse eventAffectAftercareAge-YearsAmbulatory Care FacilitiesAnxietyCaregiversCaringChronicChronic DiseaseClinicalClinical Practice GuidelineCognitionDataData CollectionDeteriorationDevelopmentDiagnosisDiscipline of NursingDiseaseElderlyEmotionalEnrollmentFatigueFoundationsFreedomFutureGoalsHematologic NeoplasmsHomeHospitalizationHospitalsHourIndependent LivingInfectionInfrastructureInfusion proceduresInstitutional Review BoardsInterventionIntervention StudiesInterviewKnowledgeLeadershipLength of StayLifeMalignant NeoplasmsManualsMeasuresMethodsModelingMonitorMotivationMovementNewly DiagnosedNursesOccupational TherapyOncologyOralOutcomeOutpatientsPainPalliative CarePatient Self-ReportPatientsPersonsPhysical therapyPreventionPrizeProceduresPrognosisProtocols documentationQuality of lifeRandomized Clinical TrialsRandomized Controlled TrialsReadinessRecommendationRegimenRegistered nurseReportingSelf ManagementSiteSleep disturbancesSpecific qualifier valueSupportive careSurveysSymptomsTest ResultTestingTherapeutic InterventionTimeTrainingTreatment EfficacyWalkingWorkWorkloadWritingacceptability and feasibilityacute carebasecancer therapychemotherapycollaborative caredaily functioningdata managementdepressive symptomsdesignefficacy trialend of lifeexercise interventionexperiencefunctional declinehealth care service utilizationhigh riskhospital readmissionimprovedimproved functioningleukemia treatmentmedical specialtiesmortality risknovelnursing interventionoperationpsychologicrecruitreduce symptomsretention rateskillssocialstandard caresymptom managementsymptom self managementtreatment duration
项目摘要
7. PROJECT SUMMARY/ABSTRACT
Acute myeloid leukemia (AML) is a serious illness of older adults (>60) which carries a high risk of mortality and
negatively impacts daily function and quality of life (QOL). Prognosis is poor; over two-thirds of patients will not
survive 5 years. Recently, approval of oral venetoclax (VEN) in addition to infusional hypomethylating agents
(HMAs) has improved treatment efficacy substantially for older adults, and protocols now typically are to receive
the first cycle of treatment during 7 days in the hospital and then return home for 21 days of treatment with
caregivers more actively involved. Patients are at high risk for fatigue, which leads to functional decline and
subsequent deterioration in quality of life (QOL), interfering with their return to independent living. We propose
to address symptoms and function management early in AML treatment using a PAlliative and Collaborative
Care inTervention (PACT) delivered by clinical staff who receive basic training in palliative and supportive care
to bridge this gap in care and address QOL. Patients highly prize freedom from symptoms and ability to move
about as important aspects of QOL. Accordingly, PACT targets symptom management and prevention of
functional decline as mechanisms through which QOL is supported. PACT is an interdisciplinary nurse-led
intervention of nursing [RN], occupational therapy [OT], physical therapy [PT] for adults ≥ 60 years of age to
begin within two days of hospital admission. Guided by the Adaptive Leadership Framework for Chronic Illness,
the PACT team works with the patient to assess and manage their symptoms (e.g. anxiety, depressive
symptoms, pain, fatigue, sleep disturbance, cognition) and to optimize function (e.g Activity Measure for Post-
Acute Care, function) to address QOL outcomes (i.e. symptoms, function domains). PACT empowers patients
with self-management skills to reduce symptoms and optimize function during this period of serious illness. The
team and patient identify and address emotional, motivational, attitudinal barriers so that the patient can do the
work required for self- management to reduce symptoms and avoid functional decline. Our primary objective is
to assess feasibility, acceptability, and change in pre and post measures of QOL, symptoms, function, and
readiness for discharge in 2 cycles (total of 60 days) of HMA + VEN regimen. We propose a two-year planning
project with these aims: 1) Determine feasibility and acceptability of study methods and examine changes in
pre- and post- treatment measures of function, patients' self-report of symptoms and QOL, and patients and
caregivers' post self-report of readiness for discharge. We will include 10 control and 10 intervention patients,
and 2) Develop and write R01 proposal based on what is learned from Aim 1. Finalize protocol, establish study
infrastructure including expanding interdisciplinary team; identify and enroll R01 sites, refine recruitment
strategy and operations procedures, procedures manual, and quality and data management plan; and obtain
IRB approval for the randomized controlled trial (RCT) R01. We address NINR's End-of-Life and Palliative Care
priorities.
7. PROJECT SUMMARY/ABSTRACT
Acute myeloid leukemia (AML) is a serious illness of older adults (>60) which carries a high risk of mortality and
negatively impacts daily function and quality of life (QOL). Prognosis is poor; over two-thirds of patients will not
survive 5 years. Recently, approval of oral venetoclax (VEN) in addition to infusional hypomethylating agents
(HMAs) has improved treatment efficacy substantially for older adults, and protocols now typically are to receive
the first cycle of treatment during 7 days in the hospital and then return home for 21 days of treatment with
caregivers more actively involved. Patients are at high risk for fatigue, which leads to functional decline and
subsequent deterioration in quality of life (QOL), interfering with their return to independent living. We propose
to address symptoms and function management early in AML treatment using a PAlliative and Collaborative
Care inTervention (PACT) delivered by clinical staff who receive basic training in palliative and supportive care
to bridge this gap in care and address QOL. Patients highly prize freedom from symptoms and ability to move
about as important aspects of QOL. Accordingly, PACT targets symptom management and prevention of
functional decline as mechanisms through which QOL is supported. PACT is an interdisciplinary nurse-led
intervention of nursing [RN], occupational therapy [OT], physical therapy [PT] for adults ≥ 60 years of age to
begin within two days of hospital admission. Guided by the Adaptive Leadership Framework for Chronic Illness,
the PACT team works with the patient to assess and manage their symptoms (e.g. anxiety, depressive
symptoms, pain, fatigue, sleep disturbance, cognition) and to optimize function (e.g Activity Measure for Post-
Acute Care, function) to address QOL outcomes (i.e. symptoms, function domains). PACT empowers patients
with self-management skills to reduce symptoms and optimize function during this period of serious illness. The
team and patient identify and address emotional, motivational, attitudinal barriers so that the patient can do the
work required for self- management to reduce symptoms and avoid functional decline. Our primary objective is
to assess feasibility, acceptability, and change in pre and post measures of QOL, symptoms, function, and
readiness for discharge in 2 cycles (total of 60 days) of HMA + VEN regimen. We propose a two-year planning
project with these aims: 1) Determine feasibility and acceptability of study methods and examine changes in
pre- and post- treatment measures of function, patients' self-report of symptoms and QOL, and patients and
caregivers' post self-report of readiness for discharge. We will include 10 control and 10 intervention patients,
and 2) Develop and write R01 proposal based on what is learned from Aim 1. Finalize protocol, establish study
infrastructure including expanding interdisciplinary team; identify and enroll R01 sites, refine recruitment
strategy and operations procedures, procedures manual, and quality and data management plan; and obtain
IRB approval for the randomized controlled trial (RCT) R01. We address NINR's End-of-Life and Palliative Care
priorities.
项目成果
期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Exploring Experiences of Bereaved Caregivers of Older Adult Patients With Acute Myeloid Leukemia.
- DOI:10.1188/22.cjon.135-139
- 发表时间:2022-04-01
- 期刊:
- 影响因子:1.1
- 作者:Poor, Elissa;Chan, Ya-Ning;Iadonisi, Katie;Tan, Kelly;Bryant, Ashley Leak
- 通讯作者:Bryant, Ashley Leak
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Ashley Leak Bryant其他文献
Rehabilitation Needs of Adults With Acute Myeloid Leukemia Undergoing Oral Venetoclax and Infusional Hypomethylating Agent
- DOI:
10.1016/j.apmr.2022.08.703 - 发表时间:
2022-12-01 - 期刊:
- 影响因子:
- 作者:
Farrell Wiggins;Alexis Petteway;Michelle LeBlanc;Laura Andrews;Korre Scott;Ya-Ning Chan;Todd Schwartz;Sue Coppola;Ashley Leak Bryant;Mackenzi Pergolotti - 通讯作者:
Mackenzi Pergolotti
How are patient-reported outcomes and symptoms being measured in adults with relapsed/refractory multiple myeloma? A systematic review
- DOI:
10.1007/s11136-019-02392-6 - 发表时间:
2019-12-17 - 期刊:
- 影响因子:2.700
- 作者:
Matthew R. LeBlanc;Rachel Hirschey;Ashley Leak Bryant;Thomas W. LeBlanc;Sophia K. Smith - 通讯作者:
Sophia K. Smith
Utilizing courageous dialogue to support minority and disadvantaged background nursing students
- DOI:
10.1016/j.profnurs.2019.06.009 - 发表时间:
2020-01-01 - 期刊:
- 影响因子:
- 作者:
Tarshe Mack Johnson;Ashley Leak Bryant;Jada Brooks;Hudson Santos;Coretta Jenerette;Mary R. Lynn;Shielda Rodgers - 通讯作者:
Shielda Rodgers
Design and implementation of a risk-adapted, longitudinal, theory-driven medication adherence intervention: A protocol for a multi-phasic, hybrid effectiveness-implementation trial
一种风险适应性、纵向、理论驱动的药物依从性干预措施的设计与实施:一项多阶段混合有效性 - 实施试验方案
- DOI:
10.1016/j.sapharm.2025.02.006 - 发表时间:
2025-06-01 - 期刊:
- 影响因子:2.800
- 作者:
Benyam Muluneh;Maurlia Upchurch;Bethel Belayneh;Emily Mackler;Ashley Leak Bryant;William A. Wood;Marcella H. Boynton;Stephanie B. Wheeler;Leah L. Zullig;Jennifer Elston Lafata - 通讯作者:
Jennifer Elston Lafata
Supporting racial, ethnic minority, and disadvantaged undergraduate nursing students with honors projects
- DOI:
10.1016/j.profnurs.2021.08.004 - 发表时间:
2022-05-01 - 期刊:
- 影响因子:
- 作者:
Ashley Leak Bryant;Beverly Foster;Cheryl Giscombe;Hudson Santos;Coretta Jenerette;Jada Brooks;Shielda Rodgers - 通讯作者:
Shielda Rodgers
Ashley Leak Bryant的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Ashley Leak Bryant', 18)}}的其他基金
A Nurse-Led Palliative and Supportive Care Intervention for Newly Diagnosed Adults with Acute Myeloid Leukemia
针对新诊断的急性髓系白血病成人的护士主导的姑息和支持护理干预措施
- 批准号:
10216694 - 财政年份:2021
- 资助金额:
$ 19.44万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 19.44万 - 项目类别:
Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 19.44万 - 项目类别:
Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 19.44万 - 项目类别:
Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 19.44万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 19.44万 - 项目类别:
Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 19.44万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 19.44万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 19.44万 - 项目类别:
EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 19.44万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 19.44万 - 项目类别:
Research Grant














{{item.name}}会员




